Movatterモバイル変換


[0]ホーム

URL:


JOP20190203A1 - بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها - Google Patents

بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها

Info

Publication number
JOP20190203A1
JOP20190203A1JOP/2019/0203AJOP20190203AJOP20190203A1JO P20190203 A1JOP20190203 A1JO P20190203A1JO P20190203 AJOP20190203 AJO P20190203AJO P20190203 A1JOP20190203 A1JO P20190203A1
Authority
JO
Jordan
Prior art keywords
methods
binding proteins
tigit antigen
abps
tigit
Prior art date
Application number
JOP/2019/0203A
Other languages
English (en)
Inventor
Nels P Nielson
Daniel Hicklin
Christopher James Nirschl
Jose-Andres Salmeron-Garcia
Cynthia Seidel-Dugan
William Winston
Philipp Steiner
Heather Brodkin
Original Assignee
Potenza Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potenza Therapeutics IncfiledCriticalPotenza Therapeutics Inc
Publication of JOP20190203A1publicationCriticalpatent/JOP20190203A1/ar

Links

Classifications

Landscapes

Abstract

يتعلق الاختراع الحالي بتقديم بروتينات رابطة لمولد الضد (ABPs) ترتبط بشكل انتقائي بـ TIGIT والأشكال المتماثلة والمتشاكلة، وتركيبات تشتمل على بروتينات ABPs. كما يتم تقديم طرق لاستخدام بروتينات ABPs، مثل الطرق العلاجية والتشخيصية.
JOP/2019/0203A2017-03-302017-06-16بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامهاJOP20190203A1 (ar)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US201762479042P2017-03-302017-03-30

Publications (1)

Publication NumberPublication Date
JOP20190203A1true JOP20190203A1 (ar)2019-09-03

Family

ID=62002506

Family Applications (1)

Application NumberTitlePriority DateFiling Date
JOP/2019/0203AJOP20190203A1 (ar)2017-03-302017-06-16بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها

Country Status (15)

CountryLink
US (1)US11453720B2 (ar)
EP (1)EP3601340A1 (ar)
JP (1)JP7335164B2 (ar)
KR (1)KR20190134605A (ar)
CN (1)CN110546163B (ar)
AU (1)AU2018243665A1 (ar)
BR (1)BR112019018378A2 (ar)
CA (1)CA3055289A1 (ar)
CO (1)CO2019009612A2 (ar)
IL (1)IL269074B2 (ar)
JO (1)JOP20190203A1 (ar)
MX (1)MX2019010440A (ar)
PH (1)PH12019502025A1 (ar)
SG (1)SG11201908092RA (ar)
WO (1)WO2018183889A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DK3356413T3 (da)2015-10-012022-04-11Potenza Therapeutics IncAnti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf
DK3618863T3 (da)2017-05-012023-08-21Agenus IncAnti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
TW202023625A (zh)2018-08-232020-07-01美商西雅圖遺傳學公司抗tigit抗體
GB201820006D0 (en)2018-12-072019-01-23LifearcHumanised anti-IL17BR antibody
KR20230024368A (ko)2020-06-182023-02-20제넨테크, 인크.항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
US12240899B2 (en)2020-06-222025-03-04Ngm Biopharmaceuticals, Inc.LAIR-1-binding agents and methods of use thereof
TW202216778A (zh)2020-07-152022-05-01美商安進公司Tigit及cd112r阻斷
AR125753A1 (es)2021-05-042023-08-09Agenus IncAnticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
WO2022242663A1 (en)*2021-05-182022-11-24Suzhou Kanova Biopharmaceutical Co., Ltd.Anti-tigit antibodies and their use
CN115466327B (zh)*2021-06-102025-07-08北京天广实生物技术股份有限公司结合tigit的抗体及其用途
JP2024527049A (ja)2021-07-282024-07-19ジェネンテック, インコーポレイテッドがんを治療するための方法及び組成物
WO2023056403A1 (en)2021-09-302023-04-06Genentech, Inc.Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
KR20250022049A (ko)2022-06-072025-02-14제넨테크, 인크.항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4560655A (en)1982-12-161985-12-24Immunex CorporationSerum-free cell culture medium and process for making same
US4657866A (en)1982-12-211987-04-14Sudhir KumarSerum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US4767704A (en)1983-10-071988-08-30Columbia University In The City Of New YorkProtein-free culture medium
GB8516415D0 (en)1985-06-281985-07-31Celltech LtdCulture of animal cells
US4927762A (en)1986-04-011990-05-22Cell Enterprises, Inc.Cell culture medium with antioxidant
US5567610A (en)1986-09-041996-10-22Bioinvent International AbMethod of producing human monoclonal antibodies and kit therefor
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)1987-03-181998-07-29Scotgen Biopharmaceuticals, Inc.Altered antibodies
US5204244A (en)1987-10-271993-04-20OncogenProduction of chimeric antibodies by homologous recombination
EP0435911B1 (en)1988-09-231996-03-13Cetus Oncology CorporationCell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en)1988-10-121988-11-16Medical Res CouncilProduction of antibodies
US5175384A (en)1988-12-051992-12-29Genpharm InternationalTransgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US5229275A (en)1990-04-261993-07-20Akzo N.V.In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en)1990-10-031992-06-16Genentech, Inc.Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en)1991-02-051996-11-05Ciba-Geigy CorporationRecombinant antibodies specific for a growth factor receptor
US6407213B1 (en)1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
ES2136092T3 (es)1991-09-231999-11-16Medical Res CouncilProcedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi)1991-10-071994-05-27Oncologix IncAnti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
EP0625200B1 (en)1992-02-062005-05-11Chiron CorporationBiosynthetic binding protein for cancer marker
DE69333082T2 (de)1992-02-112004-05-06Cell Genesys, Inc., Foster CityErzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en)1992-03-301996-11-12The Scripps Research InstituteEncoded combinatorial chemical libraries
JPH08511420A (ja)1993-06-161996-12-03セルテック・セラピューテイクス・リミテッド抗 体
US5534615A (en)1994-04-251996-07-09Genentech, Inc.Cardiac hypertrophy factor and uses therefor
US6267958B1 (en)1995-07-272001-07-31Genentech, Inc.Protein formulation
GB9603256D0 (en)1996-02-161996-04-17Wellcome FoundAntibodies
US6171586B1 (en)1997-06-132001-01-09Genentech, Inc.Antibody formulation
WO1998058964A1 (en)1997-06-241998-12-30Genentech, Inc.Methods and compositions for galactosylated glycoproteins
DE69840412D1 (de)1997-10-312009-02-12Genentech IncMethoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
ES2292236T3 (es)1998-04-022008-03-01Genentech, Inc.Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
WO1999054342A1 (en)1998-04-201999-10-28Pablo UmanaGlycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en)1998-05-081998-07-08Univ Cambridge TechBinding molecules
HUP0104865A3 (en)1999-01-152004-07-28Genentech IncPolypeptide variants with altered effector function
US6737056B1 (en)1999-01-152004-05-18Genentech, Inc.Polypeptide variants with altered effector function
EP3031917A1 (en)1999-04-092016-06-15Kyowa Hakko Kirin Co., Ltd.Method for controlling the activity of immunologically functional molecule
US20080050809A1 (en)1999-09-282008-02-28Alejandro AbuinNovel human kinases and polynucleotides encoding the same
EP1229125A4 (en)1999-10-192005-06-01Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6946292B2 (en)2000-10-062005-09-20Kyowa Hakko Kogyo Co., Ltd.Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013563B1 (ru)2000-10-062010-06-30Киова Хакко Кирин Ко., Лтд.Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US7064191B2 (en)2000-10-062006-06-20Kyowa Hakko Kogyo Co., Ltd.Process for purifying antibody
DE60144063D1 (de)2000-12-182011-03-31Dyax CorpGerichtete bibliotheken die genetisch verpackt sind
NZ592087A (en)2001-08-032012-11-30Roche Glycart AgAntibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
PL213948B1 (pl)2001-10-252013-05-31Genentech IncKompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20030215914A1 (en)2001-12-102003-11-20Erwin HoutzagerStructure for presenting desired peptide sequences
US20040093621A1 (en)2001-12-252004-05-13Kyowa Hakko Kogyo Co., LtdAntibody composition which specifically binds to CD20
JP2005535290A (ja)2002-02-222005-11-24ジェネンテック・インコーポレーテッド免疫関連疾患の治療のための組成物と方法
US7193069B2 (en)2002-03-222007-03-20Research Association For BiotechnologyFull-length cDNA
ES2362419T3 (es)2002-04-092011-07-05Kyowa Hakko Kirin Co., Ltd.Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
PL373256A1 (en)2002-04-092005-08-22Kyowa Hakko Kogyo Co, Ltd.Cells with modified genome
JPWO2003085119A1 (ja)2002-04-092005-08-11協和醗酵工業株式会社抗体組成物のFcγ受容体IIIaに対する結合活性を高める方法
CA2481920A1 (en)2002-04-092003-10-16Kyowa Hakko Kogyo Co., Ltd.Antibody composition-containing medicament
EP1502603A4 (en)2002-04-092006-12-13Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
AU2003236015A1 (en)2002-04-092003-10-20Kyowa Hakko Kirin Co., Ltd.Process for producing antibody composition
ATE493433T1 (de)2002-09-112011-01-15Genentech IncNeue zusammensetzung und verfahren zur behandlung von immunerkrankungen
US7361740B2 (en)2002-10-152008-04-22Pdl Biopharma, Inc.Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en)2002-12-162011-03-30Genentech, Inc.Immunoglobulin variants and uses thereof
KR101199789B1 (ko)2003-03-242012-11-09더 스크립스 리서치 인스티튜트종양 성장 억제 dna 백신
US20080241884A1 (en)2003-10-082008-10-02Kenya ShitaraFused Protein Composition
US20070134759A1 (en)2003-10-092007-06-14Harue NishiyaProcess for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DE602004026470D1 (de)2003-11-052010-05-20Roche Glycart AgFc-rezeptor und effektorfunktion
JPWO2005053742A1 (ja)2003-12-042007-06-28協和醗酵工業株式会社抗体組成物を含有する医薬
PL1737891T3 (pl)2004-04-132013-08-30Hoffmann La RochePrzeciwciała przeciw selektynie p
TWI309240B (en)2004-09-172009-05-01Hoffmann La RocheAnti-ox40l antibodies
WO2006034488A2 (en)2004-09-232006-03-30Genentech, Inc.Cysteine engineered antibodies and conjugates
JO3000B1 (ar)2004-10-202016-09-05Genentech Incمركبات أجسام مضادة .
WO2006124667A2 (en)2005-05-122006-11-23Zymogenetics, Inc.Compositions and methods for modulating immune responses
EP1907001B1 (en)2005-06-172015-07-15Merck Sharp & Dohme Corp.Ilt3 binding molecules and uses therefor
US20090181380A1 (en)2005-12-192009-07-16Abdelmajid BelouchiGenemap of the human genes associated with crohn's disease
US20080226635A1 (en)2006-12-222008-09-18Hans KollAntibodies against insulin-like growth factor I receptor and uses thereof
CN102131828B (zh)2007-06-182015-06-17默沙东有限责任公司针对人程序性死亡受体pd-1的抗体
US8877688B2 (en)2007-09-142014-11-04Adimab, LlcRationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (ja)2007-09-142016-06-15アディマブ, エルエルシー合理的に設計された、合成抗体ライブラリおよびその使用
CN110082533B (zh)2008-04-092023-01-10健泰科生物技术公司用于免疫相关疾病的治疗的新组合物和方法
CN102666582B (zh)2009-12-222016-03-30弗·哈夫曼-拉罗切有限公司序列依赖性聚集
EP2388336A1 (en)2010-05-192011-11-23Signature Diagnostics AGMethod and kits for diagnosing colorectal cancer
BR112012031329A2 (pt)2010-06-092016-10-11Zymogenetics Incproteínas de fusão diméricas vstm3 e composições e métodos relacionados
US8907053B2 (en)2010-06-252014-12-09Aurigene Discovery Technologies LimitedImmunosuppression modulating compounds
AU2011279073B2 (en)2010-07-162016-06-09Adimab, LlcAntibody libraries
JP5909239B2 (ja)2010-10-262016-04-26マーズ インコーポレイテッドアルギナーゼ阻害剤としてのボロネート
DE102011005235B4 (de)2011-03-082017-05-24Sirs-Lab GmbhVerfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
HK1206636A1 (zh)2012-04-022016-01-15Modernatx, Inc.用於制备肿瘤相关蛋白和多肽的修饰的多核苷酸
WO2013184912A2 (en)2012-06-062013-12-12Oncomed Pharmaceuticals, Inc.Binding agents that modulate the hippo pathway and uses thereof
EP3677310A1 (en)*2012-10-082020-07-08St. Jude Children's Research HospitalTherapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
PL2925350T3 (pl)2012-12-032019-07-31Bristol-Myers Squibb CompanyZwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
NZ709059A (en)2012-12-042016-11-25Oncomed Pharm IncImmunotherapy with binding agents
EP2991679A4 (en)2013-04-292016-12-07Adimab Llc POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE
HRP20201404T1 (hr)2013-07-162020-11-27F. Hoffmann - La Roche AgPostupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
MD4733C1 (ro)2014-08-192021-07-31Merck Sharp & Dohme CorpAnticorpi anti-TIGIT
KR20170072343A (ko)2014-11-062017-06-26제넨테크, 인크.Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
KR102644115B1 (ko)*2014-12-232024-03-05브리스톨-마이어스 스큅 컴퍼니Tigit에 대한 항체
TWI715587B (zh)*2015-05-282021-01-11美商安可美德藥物股份有限公司Tigit結合劑和彼之用途
CN108137691B (zh)*2015-09-022021-10-19耶路撒冷希伯来大学伊萨姆研究发展有限公司特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
CN106554347B (zh)2015-09-252020-10-30浙江博生医药有限公司Egfr激酶抑制剂及其制备方法和应用
DK3356413T3 (da)2015-10-012022-04-11Potenza Therapeutics IncAnti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf
JOP20190134A1 (ar)*2016-12-232019-06-02Potenza Therapeutics Incبروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CA3126735A1 (en)*2019-01-112020-07-16Omeros CorporationMethods and compositions for treating cancer

Also Published As

Publication numberPublication date
JP2020512973A (ja)2020-04-30
WO2018183889A1 (en)2018-10-04
CN110546163A (zh)2019-12-06
MX2019010440A (es)2020-02-07
IL269074B2 (en)2024-12-01
RU2019127786A3 (ar)2021-07-22
CO2019009612A2 (es)2020-01-17
CN110546163B (zh)2024-03-29
US20200095324A1 (en)2020-03-26
EP3601340A1 (en)2020-02-05
PH12019502025A1 (en)2020-06-01
RU2019127786A (ru)2021-04-30
IL269074B1 (en)2024-08-01
JP7335164B2 (ja)2023-08-29
KR20190134605A (ko)2019-12-04
SG11201908092RA (en)2019-10-30
CA3055289A1 (en)2018-10-04
BR112019018378A2 (pt)2020-04-07
US11453720B2 (en)2022-09-27
AU2018243665A1 (en)2019-09-26
IL269074A (en)2019-11-28

Similar Documents

PublicationPublication DateTitle
PH12018500714A1 (en)Anti-tigit antigen-binding proteins and methods of use thereof
PH12019501405A1 (en)Anti-neuropilin antigen-binding proteins and methods of use thereof
PH12020500240A1 (en)Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
PH12019502025A1 (en)Anti-tigit antigen-binding proteins and methods of use thereof
ZA202201874B (en)Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
WO2017087901A3 (en)Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
MX2021007692A (es)Proteinas de union anti-pd-1 y metodos de uso de las mismas.
MX2023010042A (es)Polinucleotidos moduladores.
WO2016077397A3 (en)Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
WO2016014434A3 (en)Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
MX2023008686A (es)Polinucleotidos moduladores.
MX2021007848A (es)Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
MX2019005821A (es)Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas.
MX2017003211A (es)Anticuerpos anti-met y composiciones.
PH12019502694A1 (en)Anti-trkb antibodies
PH12018501279A1 (en)Compositions comprising 15-hepe and methods of using the same
NZ715582A (en)Lectin-like oxidized ldl receptor 1 antibodies and methods of use
WO2018129451A3 (en)Anti-fgfr antibodies and methods of use
MX2022002635A (es)Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en)Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2022015948A (es)Proteínas de unión anti-ctla-4 y métodos de uso de estas.
MX2021007846A (es)Proteinas que se unen a anti-pd-l1 y metodos de uso de las mismas.

[8]ページ先頭

©2009-2025 Movatter.jp